Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal

NCT03541356 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

COMBINATION_PRODUCT: Placebo
COMBINATION_PRODUCT: L-dopa 35 mg
COMBINATION_PRODUCT: L-dopa 70mg
COMBINATION_PRODUCT: L-dopa 140 mg
COMBINATION_PRODUCT: L-dopa 70mg/carbidopa 7mg

Sponsor

Impel Pharmaceuticals